Efficacy of Lenalidomide With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma
Status:
Completed
Trial end date:
2018-01-11
Target enrollment:
Participant gender:
Summary
Because Primary Central Nervous System Lymphoma (PCNSL) are mainly diffuse large B-cell
lymphoma of the activated B cells (ABC) type, the investigators hypothesize that the synergy
of lenalidomide with rituximab shown in systemic non-Hodgkin's lymphoma (NHL) could be
observed in PCNSL.
This study will assess the efficiency of the the combination of lenalidomide and rituximab in
relapsed/refractory PCNSL, and the efficiency of a maintenance treatment with lenalidomide
alone in maintaining the response.
Phase:
Phase 2
Details
Lead Sponsor:
Institut Curie
Collaborators:
Central Hospital, Nancy, France Centre Henri Becquerel Centre Hospitalier Universitaire, Amiens Centre Leon Berard Groupe Hospitalier Pitie-Salpetriere Institut Bergonié University Hospital, Clermont-Ferrand University Hospital, Grenoble University Hospital, Lille University Hospital, Tours